Marina Gonçalves Diniz

Prof. Marina Gonçalves Diniz


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
MDMarina Gonçalves Diniz
Marina Gonçalves Diniz
CGCarolina Cavalieri Gomes
Carolina Cavalieri Gomes
BGBruna Viana Antonini Guimarães
Bruna Viana Antonini Guimarães
WCWagner Henriques Castro
Wagner Henriques Castro
JLJúlio César Tanos Lacerda
Júlio César Tanos Lacerda
RGRicardo Santiago Gomez
Ricardo Santiago Gomez

1 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
CGCarolina Cavalieri Gomes
Carolina Cavalieri Gomes
TGTenzin Gayden
Tenzin Gayden
ABAndrea Bajic
Andrea Bajic
OHOsama Harraz
Osama Harraz
JPJonathan Pratt
Jonathan Pratt
NJNada Jabado
Nada Jabado
Giant cell lesions of the jaw (GCLJ) are debilitating tumors of unknown origin with limited available therapies. Here, we analyze 58 sporadic samples using next generation or targeted sequencing and report somatic, heterozygous, gain-of-function mutations inKRAS, FGFR1, and p.M713V/I-TRPV4in 72% (42/58) of GCLJ.TRPV4p.M713V/I mutations are exclusive to central GCLJ and occur at a critical position adjacent to the cation permeable pore of the channel. Expression of TRPV4 mutants in HEK293 cells leads to increased cell death, as well as increased constitutive and stimulated channel activity, both of which can be prevented using TRPV4 antagonists. Furthermore, these mutations induce sustained activation of ERK1/2, indicating that their effects converge with that ofKRASandFGFR1mutations on the activation of the MAPK pathway in GCLJ. Our data extend the spectrum of TRPV4 channelopathies and provide rationale for the use of TRPV4 and RAS/MAPK antagonists at the bedside in GCLJ.

1 March 2007 in Archives of Oral Biology
Verified
Journal Article
Closed access
André Luiz Sena GuimarãesAndré Luiz Sena Guimarães
André Luiz Sena Guimarães
JCJeane de Fátima Correia-Silva
Jeane de Fátima Correia-Silva
ASAlessandra Rosa de Sá
Alessandra Rosa de Sá
JVJunia Maria Netto Victória
Junia Maria Netto Victória
MDMarina Gonçalves Diniz
Marina Gonçalves Diniz
RGRicardo Santiago Gomez
Ricardo Santiago Gomez

1 June 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
BCBruna Pizziolo Coura
Bruna Pizziolo Coura
VBVanessa Fátima Bernardes
Vanessa Fátima Bernardes
SSSílvia Ferreira de Sousa
Sílvia Ferreira de Sousa
JFJosiane Alves França
Josiane Alves França
NPNúbia Braga Pereira
Núbia Braga Pereira
CGCarolina Cavalieri Gomes
Carolina Cavalieri Gomes

2 July 2010 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
PDF file
CGCarolina Cavalieri Gomes
Carolina Cavalieri Gomes
ADAlessandra Pires Duarte
Alessandra Pires Duarte
MDMarina Gonçalves Diniz
Marina Gonçalves Diniz
RGRicardo Santiago Gomez
Ricardo Santiago Gomez

1 September 2017 in Oral Oncology
Verified
Journal Article
Open access
MDMarina Gonçalves Diniz
Marina Gonçalves Diniz
CGCarolina Cavalieri Gomes
Carolina Cavalieri Gomes
SSSílvia Ferreira de Sousa
Sílvia Ferreira de Sousa
GXGuilherme Machado Xavier
Guilherme Machado Xavier
RGRicardo Santiago Gomez
Ricardo Santiago Gomez
The first step towards the prevention of cancer is to develop an in-depth understanding of tumourigenesis and the molecular basis of malignant transformation. What drives tumour initiation? Why do most benign tumours fail to metastasize? Oncogenic mutations, previously considered to be the hallmark drivers of cancers, are reported in benign cysts and tumours, including those that have an odontogenic origin. Despite the presence of such alterations, the vast majority of odontogenic lesions are benign and never progress to the stage of malignant transformation. As these lesions are likely to develop due to developmental defects, it is possible that they harbour quiet genomes. Now the question arises - do they result from DNA replication errors? Specific candidate genes have been sequenced in odontogenic lesions, revealing recurrent BRAF mutation in the case of ameloblastoma, KRAS mutation in adenomatoid odontogenic tumours, PTCH1 mutation in odontogenic keratocysts, and CTNNB1 (Beta-catenin) mutation in calcifying odontogenic cysts. Studies on these benign and rare entities might reveal important information about the tumorigenic process and the mechanisms that hinder/halt neoplastic progression. This is because the role of relatively common oncogenic mutations seems to be context dependent. In this review, each mutation signature of the odontogenic lesion and the affected signalling pathways are discussed in the context of tooth development and tumorigenesis. Furthermore, behavioural differences between different types of odontogenic lesions are explored and discussed based on the molecular alteration described. This review also includes the employment of molecular results for guiding therapeutic approaches towards odontogenic lesions.